• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library

    UCB’s Kygevvi Receives Approval in US

    FDA

    UCB Canada`s Rystiggo Receives Approval in Canada

    HEALTH CANADA

    UCB`s Biologic Bimzelx (Bimekizumab) Receives Suppl. Approval in US

    FDA

    UCB`s Biologic Bimzelx (Bimekizumab) Receives Suppl Approval in US

    FDA

    UCB`s Biologic Cimzia (certolizumab pegol) Receives Approval in the U.S.

    FDA

    UCB`s Biologic Bimzelx (bimekizumab) Receives Approval in the U.S.

    FDA

    UCB`s Biologic Cimzia (Certolizumab Pegol) Receives Approval in the U.S.

    FDA

    UCB`s Vimpat Receives Approval in Europe

    EMA

    UCB Pharma`s Bimzlex (bimekizumab) Receives Approval in Europe

    EMA

    UCB Inc`s Cimzia (Certolizumab Pegol) Receives Supplemental Approval In US

    FDA

    UCB Inc`s Supplement Cimzia (Certolizumab Pegol) Receives Approval In US

    FDA

    UCB Inc`s Briviact (Brivaracetam) Oral solutions approved in US for Partial-Onset Seizures

    FDA

    UCB Inc`s Briviact (Brivaracetam) Injections approved in US for Partial-Onset Seizures

    FDA

    UCB Inc`s Briviact (Brivaracetam) Tablets approved in US for Partial-Onset Seizures

    FDA

    UCB Pharma SA`s Briviact receives marketing autorisation in EU for epilepsy

    EMA

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.